



Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, *Candida albicans* does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of *Candida* (*C. tropicalis*, *C. guilliermondi*, *C. krusei*, and *C. stellatoidea*) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed.

Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

## **INDICATIONS AND USAGE**

Nystatin Cream USP is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by *Candida albicans* and other susceptible *Candida* species.

**Nystatin Cream USP is not indicated for systemic, oral, intravaginal or ophthalmic use.**

## **CONTRAINDICATIONS**

Nystatin Cream USP is contraindicated in patients with a history of hypersensitivity to any of its components.

## **PRECAUTIONS**

### **General -**

**Nystatin Cream USP should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.**

If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.

### **Information for Patients -**

Patients using this medication should receive the following information and instructions:

1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.
2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.
3. If symptoms of irritation develop, the patient should be advised to notify the physician promptly.

### **Laboratory Tests -**

If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility -**

No long-term animal studies have been performed to evaluate the carcinogenic potential of Nystatin. No studies have been performed to determine the mutagenicity of Nystatin or its effects on male or female fertility

### **Pregnancy: Teratogenic Effects: Category C -**

Animal reproduction studies have not been conducted with any Nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical preparations should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

### **Nursing Mothers -**

It is not known whether Nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

### **Pediatric Use -**

Safety and effectiveness have been established in the pediatric population from birth to 16 years (see **DOSAGE AND ADMINISTRATION**).

### **Geriatric Use -**

Clinical studies with nystatin cream did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

## **ADVERSE REACTIONS**

The frequency of adverse events reported in patients using Nystatin Cream USP is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application (see **PRECAUTIONS-General**).

## **DOSAGE AND ADMINISTRATION**

Very moist lesions are best treated with nystatin topical dusting powder.

### **Adults and Pediatric Patients (Neonates and Older):**

Apply liberally to affected areas twice daily or as indicated until healing is complete.

## **HOW SUPPLIED**

Nystatin Cream USP (100,000 USP Nystatin Units per gram) is a yellow cream available

as follows:

15 g tube (NDC 68788-8436-3)

**Storage**

Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].

Manufactured By Perrigo plc  
Bronx, NY 10457

Distributed By  
Padagis  
Allegan, MI 49010  
www.padagis.com

Rev 02-22

1P600 RC JX2

**Relabeled By: Preferred Pharmaceuticals Inc.**

**Principal Display Panel**

Rx Only

NDC 68788-8436-1

Nystatin Cream USP

(100,000 USP Nystatin Units)

NET WT 30 g

<p><b>Nystatin Cream USP 100,000 units per gram</b></p> <p>Generic for Mycostatin</p> <p>Each gram contains: 100,000 units of nystatin in an aqueous cream base.</p> <p><b>Pkg Size:</b> Exp Date: Lot#: Batch#: Ins: Mfg: Perrigo Company, Bronx, NY Prod#:</p> <p><b>Warning</b> Keep out of the reach of children. RX Only. For external use only. Not for ophthalmic use. Store at 20° to 25°C (68° to 77°F) See USP Controlled Room Temperature. Avoid freezing. Rx Only.</p>	<p><b>PREFERRED</b> Pharmaceuticals, Inc. Anahaim, Ca 92807</p>  <p><b>Directions English</b> Apply externally _____ times a day.</p>  <p><b>Instrucciones Espanol:</b> Aplique externamente _____ veces al dia.</p>	<p>CAUTION: Federal law PROHIBITS transfer of this drug to any person other than the patient for whom it was prescribed</p>	<p>Nystatin Cream USP 100,000 units per gram Qty: Ins: Lot#: Bat#:</p> <p>Prod# (NDC):</p> <p>Nystatin Cream USP 100,000 units per gram Qty: Ins: Lot#: Bat#: Prod# (NDC):</p> <p>Nystatin Cream USP 100,000 units per gram Qty: Insurance NDC: Lot#: Bat#:</p> <p>Nystatin Cream USP 100,000 units per gram Qty: Ins: Lot#: Bat#: Prod# (NDC):</p>	<p>Log Chart Billing Patient</p>
--	--	---	---	--

<b>NYSTATIN</b>			
nystatin cream			
<b>Product Information</b>			
HUMAN PRESCRIPTION	Item Code	NDC: 68788-8436-1 / NDC: 45000	

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:68788-8436(NDC:45802-059)	
<b>Route of Administration</b>	TOPICAL			
<b>Active Ingredient/Active Moiety</b>				
<b>Ingredient Name</b>		<b>Basis of Strength</b>	<b>Strength</b>	
Nystatin (UNII: BDF1O1C72E) (Nystatin - UNII:BDF1O1C72E)		Nystatin	100000 [USP'U] in 1 g	
<b>Inactive Ingredients</b>				
<b>Ingredient Name</b>			<b>Strength</b>	
GLYCERIN (UNII: PDC6A3C0OX)				
ISOPROPYL MYRISTATE (UNII: 0RE8K4LNJS)				
LACTIC ACID, UNSPECIFIED FORM (UNII: 33X04XA5AT)				
WATER (UNII: 059QF0KO0R)				
SODIUM HYDROXIDE (UNII: 55X04QC32I)				
SORBIC ACID (UNII: X045WJ989B)				
<b>Packaging</b>				
<b>#</b>	<b>Item Code</b>	<b>Package Description</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
1	NDC:68788-8436-1	1 in 1 CARTON	04/28/2023	
1		15 g in 1 TUBE; Type 0: Not a Combination Product		
<b>Marketing Information</b>				
<b>Marketing Category</b>	<b>Application Number or Monograph Citation</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>	
ANDA	ANDA062225	04/28/2023		

**Labeler** - Preferred Pharmaceuticals Inc. (791119022)

**Registrant** - Preferred Pharmaceuticals Inc. (791119022)

**Establishment**

<b>Name</b>	<b>Address</b>	<b>ID/FEI</b>	<b>Business Operations</b>
Preferred Pharmaceuticals Inc.		791119022	RELABEL(68788-8436)